Also as succinctly summarized here:

Something sounds different in this #SABCS24 session. The science here is a little more engaging 😁.

Very true. I think cross talk of HER2 and ER has been very poorly addressed. Blocking HER2 up-regulates ER expression and mandates ER blockade. Yet, very little mention in NCCN as an afterthought!

Hyping for my smart dear friend @yabdoumd.bsky.social from UNC, who is moderating Poster Spotlight Session 9: ctDNA Uses for Minimal Residual Disease Testing, Tumor Evolution, and Novel Technologies. Tomorrow at 7 AM at Stars at Night 3-4

#SABCS2024
#bcsm
@sabcs.bsky.social

Another great study run by TBCRC and lead by my dear colleague Dr. Julie Nangia at @bcmhouston.bs. #042 used Ruxolitinib for 10-20 days b4 surgery to inhibit pSTAT5 pathway in premalig AH/CIS (ductal/lobular). 1ry endpoint is apoptosis by Caspase3 drop pending. Congrats

#SABCS24
#bcsm

Sobering data on 7-year IBC outcome from @mdanderson.bsky.social presented by superstar Dr. Azadeh Nasrazadani. 7-year OS % 7, 24, 50, 55 in TNBC, ER+ HER2-, ER- HER2+ and ER+HER2+. CDK4/6i benefit low compared with historic cohorts. @naborala.bsky.social we need better Rx.

#SABCS24
#bcsm

A nice poster on TDxD resistance presented by my dear friend Mohamed Gouda from MDACC. Almost 1/3rd of Pts lost HER2 IHC, and another 1/3 decreased transcript.

Did PAM50 change?

#SABCS24
#bcsm

Dr Luca Malorni presented very thought provoking TOUCH study in ER/HER2+ with neoadj HP/Taxol vs HP/Palbo Letrozole. pCR 32.9 vs 33.3%. In high RBsig, Palbo/AI did better!

Another no-chemo Rx next to KRISTINE. Qs: PAM50 role? CDK/ET replacing Taxol in NACT? What about CDK in ABC?

#SABCS24
#bcsm

Great data on PADMA presented by Dr. Loibl in 1st L HR+ MBC btw Chemo + maintenance ET vs. Palbo + ET. Palbo more than doubled time to treatment failure (6 vs 17 months)

Same data in RIGHT CHOICE with PFS 21.8 vs 12.8 months in RiboET vs CT. No more chemo 1st L!
#SABCS24
#bcsm
@sabcs.bsky.social

An important money slide in discordance of variants between cfDNA and tumor testing. Panel by stellar Dr. Ellen Landsberger who shared some tough Qs on utility of cfDNA from Pt advocates POV.

Take home: Breast CA has high rate of novel variants on cfDNA not on tumor

#SABCS24
@sabcs.bsky.social

OFS for fertility perservation is severely underutilized. AYA discussion with young Pts is paramount & need routine workflow

On separate note, there remains a gap in using OFS for HR+ HER2+. Data are a little different (T/OFS better than E/OFS) but they were small percent of population.

#SABCS24

Everyday there is at least one TBCRC presentation in #SABCS24. Such a wonderful consortium and amazing dedicated investigators. Since inception, 64 breast trials (and counting). @hoperugo.bsky.social @ptarantinomd.bsky.social @meghanflanigan.bsky.social #bcsm

This was a wonderful session. Highly recommend to rewatch for those who have tough time where to start applying for funds. Foundational, NIH, and industry venues. Also internal CCSG funds and SPORE CDA. @stolaney1.bsky.social @Minetta Liu, @Larissa Korde @Brenda Ernst #SABCS24 #bcsm